Neurodevelopmental disorders (NDDs) encompass a range of conditions that begin during the developmental stage and cause deficits that lead to disruptions in normal functioning. One class of chemicals that is of increasing concern for neurodevelopmental disorders is made up of per- and polyfluoroalkyl substances (PFAS). In this comprehensive literature review, we investigated data from epidemiological studies to understand the connection between PFAS exposure and neurodevelopmental endpoints such as cognitive function, intelligence (IQ), and memory, along with behavioral changes like Attention-Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorders (ASD). When we reviewed the findings from individual studies that analyzed PFAS levels in biological samples and their association with NDD, we concluded that there was a correlation between PFAS and neurodevelopmental disorders. The findings suggest that children exposed to higher PFAS levels could potentially have an increased risk of ASD and ADHD along with an inhibitory effect on IQ. While the results vary from one study to another, there is increasing association between PFAS exposure and neurodevelopmental disorders. Importantly, the findings provide valuable insights into the adverse effects associated with PFAS exposure and neurodevelopment.
Per- and polyfluoroalkyl substances (PFAS) are synthetic chemicals used in various products, such as firefighting foams and non-stick cookware, due to their resistance to heat and degradation. However, these same properties make them persistent in the environment and human body, raising public health concerns. This study selected eleven PFAS commonly found in drinking water and exposed Caenorhabditis elegans to concentrations ranging from 0.1 to 200 µM to assess neurodevelopmental toxicity using a high-throughput, high-content screening (HTS) platform coupled with artificial intelligence for image analysis. Our findings showed that PFAS such as 6:2 FTS, HFPO-DA, PFBA, PFBS, PFHxA, and PFOS inhibited dopaminergic neuron activity, with fluorescence intensity reductions observed across concentrations from 0.1 to 100 µM. PFOS and PFBS also disrupted synaptic transmission, causing reduced motility and increased paralysis in aldicarb-induced assays, with the most pronounced effects at higher concentrations. These impairments in both neuron activity and synaptic function led to behavioral deficits. Notably, PFOS was one of the most toxic PFAS, affecting multiple neurodevelopmental endpoints. These results emphasize the developmental risks of PFAS exposure, highlighting the impact of both individual compounds and mixtures on neurodevelopment. This knowledge is essential for assessing PFAS-related health risks and informing mitigation strategies.
The use of CRISPR‐Cas proteins for the creation of multiplex genome engineering represents an important avenue for crop improvement, and further improvements for creation of knock‐in plant lines via CRISPR‐based technologies may enable the high‐throughput creation of designer alleles. To circumvent limitations of the commonly used CRISPR‐Cas9 system for multiplex genome engineering, we explored the use of Moraxella bovoculi 3 Cas12a (Mb3Cas12a) for multiplex genome editing in Arabidopsis thaliana. We identified optimized cis‐regulatory sequences for driving expression of single‐transcript multiplex crRNA arrays in A. thaliana, resulting in stable germline transmission of Mb3Cas12a‐edited alleles at multiple target sites. By utilizing this system, we demonstrate single‐transcript multiplexed genome engineering using of up to 13 crRNA targets. We further show high target specificity of Mb3Cas12a‐based genome editing via whole‐genome sequencing. Taken together, our method provides a simplified platform for efficient multiplex genome engineering in plant‐based systems.
The use of SABR in patients with oligometastases has been associated with improvements in progression-free survival and overall survival. Quality of life (QoL) is of substantial importance in the metastatic setting, since treatments have historically been considered palliative-intent. However, randomized data assessing the longitudinal QoL impact of SABR in the oligometastatic setting are lacking. Herein we report longitudinal QoL outcomes from the SABR-COMET randomized trial.